Faeth Therapeutics, Inc.
FTH· Nasdaq
Released Aug 4, 2026, before the open
10-Q filed Aug 4, 2026, 35 days after period end · 0001193125-26-331562
| Metric | Q2 2026 | Q2 2025 | Q2 2024 | Q2 2023 |
|---|---|---|---|---|
| Net Income | -$16.01M | -$4.94M | -$7.14M | -$9.39M |
| EPS Diluted | -$2.84 | -$3.91 | -$5.69 | -$0.31 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Faeth Therapeutics, Inc. · CIK 1829802 · Engraved from SEC EDGAR